Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals Inc (NQ: TERN )

8.140 -0.080 (-0.97%)
Streaming Delayed Price Updated: 10:00 AM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 170,679
Open 8.290
Bid (Size) 8.130 (1)
Ask (Size) 8.150 (1)
Prev. Close 8.220
Today's Range 8.050 - 8.425
52wk Range 3.260 - 10.03
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+25.62%
+25.62%
1 Month
-9.66%
-9.66%
3 Month
+28.80%
+28.80%
6 Month
+7.67%
+7.67%
1 Year
+44.84%
+44.84%

More News

Read More
3 Biotech Stocks That Could Have Investors Grinning Soon
Via InvestorPlace
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
TERN Stock Earnings: Terns Pharma Meets EPS for Q4 2023
Via InvestorPlace
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024
Via InvestorPlace
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Announces Leadership Changes
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Via The Motley Fool
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.